OMEROS CORP Unrealized Gain (Loss) on Derivatives
OMEROS CORP (OMER) reported Unrealized Gain (Loss) on Derivatives of $11.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-08-12
- OMEROS CORP unrealized gain (loss) on derivatives for the quarter ending 2026-06-30 was $11.45M, a 39.48% increase year-over-year.
- OMEROS CORP unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was $73.15M.
- OMEROS CORP unrealized gain (loss) on derivatives for the quarter ending 2025-12-31 was -$136.04M, a 716084.21% decline year-over-year.
- OMEROS CORP unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was -$8.82M.
- OMEROS CORP unrealized gain (loss) on derivatives for fiscal 2025 was -$136.72M, a 719663.16% decline from fiscal 2024.
- OMEROS CORP unrealized gain (loss) on derivatives for fiscal 2024 was $19.00K.
- OMEROS CORP unrealized gain (loss) on derivatives for fiscal 2023 was $0.00.
- OMEROS CORP unrealized gain (loss) on derivatives for fiscal 2020 was -$838.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.45M 10-Q · filed 2026-08-12 | $84.59M 10-Q · filed 2026-08-12 | -$51.44M derived: sum of 3 quarters · filed 2026-08-12 | -$60.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $73.15M 10-Q · filed 2026-05-13 | -$62.89M derived: sum of 2 quarters · filed 2026-05-13 | -$71.71M derived: sum of 3 quarters · filed 2026-05-13 | -$63.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$136.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$144.86M derived: sum of 2 quarters · filed 2026-03-31 | -$136.65M derived: sum of 3 quarters · filed 2026-08-12 | -$136.72M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$8.82M 10-Q · filed 2025-11-13 | -$615.00K derived: sum of 2 quarters · filed 2026-08-12 | -$680.00K 10-Q · filed 2025-11-13 | -$661.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $8.21M 10-Q · filed 2026-08-12 | $8.14M 10-Q · filed 2026-08-12 | $8.16M derived: sum of 3 quarters · filed 2026-08-12 | $8.16M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$65.00K 10-Q · filed 2026-05-13 | -$46.00K derived: sum of 2 quarters · filed 2026-05-13 | -$46.00K derived: sum of 3 quarters · filed 2026-05-13 | -$46.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $19.00K derived: sum of 2 quarters · filed 2026-03-31 | $19.00K derived: sum of 3 quarters · filed 2026-03-31 | $19.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-31 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$838.00K 10-K · filed 2023-03-13 | ||
| 2020-09-30 | -$838.00K 10-Q · filed 2021-11-09 | |||
| 2018-12-31 | -$354.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |